Milgamma N (Benfotiamine, Cyanocobalamin, Pyridoxine Hydrochloride)

Benfotiamine supplies thiamine that participates in carbohydrate metabolism, cyanocobalamin provides cobalamin needed for red blood cell formation and nerve health, and pyridoxine acts as a cofactor for amino‑acid metabolism and neurotransmitter synthesis. Together they enhance enzymatic pathways essential for neuronal function and energy production.

The appropriate dose of Milgamma N is determined by the prescribing healthcare professional based on the individual’s deficiency status, age, weight and clinical condition. Patients should follow the prescriber’s instructions and not alter the dosage without medical advice.

Safety data for Milgamma N in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Milgamma N, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Milgamma N combines a lipid‑soluble thiamine derivative (benfotiamine) with standard cyanocobalamin and pyridoxine, offering potentially higher bioavailability of vitamin B1 compared with plain thiamine salts. Its composition is similar to other B‑complex formulations but the specific inclusion of benfotiamine may provide added benefit for carbohydrate metabolism and nerve support.

Milgamma N should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure the package is tightly closed to maintain stability.

Milgamma N is taken orally, typically with water. The tablet should be swallowed whole and not chewed or crushed unless directed by a healthcare professional.

Serious but rare adverse reactions include anaphylaxis, Stevens‑Johnson syndrome and hemolytic anemia. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, widespread skin rash, blistering, or sudden onset of fatigue and jaundice.

Milgamma N is contraindicated in individuals with known hypersensitivity to any of its ingredients. Patients with severe renal impairment should use it only under medical supervision, and pregnant or breastfeeding women should only take it when clearly indicated by a healthcare professional.